Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. has developed the RaniPill capsule, a proprietary technology that allows for the oral administration of biologics, thus providing a convenient alternative to painful injections. Strong preclinical data reveals that RaniPill demonstrates bioavailability of approximately 111%, equating to systemic exposure comparable to subcutaneous delivery, which supports the advancement of their pipeline toward first-in-human studies in 2025. Furthermore, the company is well-capitalized with a cash runway projected through 2028, positioning it favorably for growth amid increasing interest and M&A activity in the next-generation oral drug delivery market.

Bears say

Rani Therapeutics Holdings Inc faces several challenges that contribute to a negative outlook on its stock. Firstly, there are concerns regarding management turnover, which may disrupt clinical development progress and negatively affect share performance, casting doubt on the company's ability to gain market share in a competitive landscape. Additionally, uncertainties surrounding reimbursement levels and the potential for competing market entrants could adversely impact revenue forecasts and sales of Rani's product offerings, further exacerbating the company's financial vulnerability.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.